Latest Probiotics News

Page 1 of 6
Biome Australia has secured an exclusive mainland China cross-border e-commerce agreement with H&S Global, targeting A$2.0 million in Year 1 purchases from an early 2027 launch. The target is larger than Biome’s entire FY26 international sales, but the company will fund 25% of Year 1 invoiced value in marketing and operational support.
Ada Torres
Ada Torres
9 Nov 2026
Terragen has completed the induction of 10,600 cattle into its largest feedlot trial and secured Brazilian approval for its probiotic feed additive. But customer receipts fell to $255,000 for the September quarter, while cash declined to $5.73 million amid a CEO departure and chair transition.
Ada Torres
Ada Torres
30 Oct 2026
Biome Australia has reported record pharmacy sell-through, further market-share gains and positive operating cash flow as it begins manufacturing Activated Probiotics domestically. The quarter also moved its China expansion and BMB18 clinical trial closer to key execution milestones.
Ada Torres
Ada Torres
26 Oct 2026
Biome Australia Limited (ASX:BIO) delivered its second consecutive profitable year in FY26, with revenue rising 30% to $23.9 million and operating cash flow turning positive. But the headline $3.6 million profit includes a $2.4 million deferred tax benefit, leaving FY27 execution as the real test of the company’s growth plan.
Ada Torres
Ada Torres
22 Sept 2026
Nuchev has inked a consignment-based distribution deal to launch the Kuci women’s health probiotic range nationally through Chemist Warehouse, marking a strategic expansion into women’s health.
Ada Torres
Ada Torres
28 Aug 2026
Biome Australia has delivered a standout FY26 with sales up 30% to $23.9 million and net profit after tax soaring to $3.6 million, bolstered by a non-cash deferred tax asset. The company strengthened its balance sheet while expanding manufacturing and international distribution.
Ada Torres
Ada Torres
26 Aug 2026
Terragen Holdings posted a slight increase in net loss to AUD 3.75 million for FY2026, while advancing key commercial trials and securing a $7 million equity raise to fuel growth.
Ada Torres
Ada Torres
25 Aug 2026
BLIS Technologies has kicked off FY27 with a 42% revenue increase and a return to EBITDA profitability, driven by strong B2B growth in Asia Pacific and China.
Ada Torres
Ada Torres
20 Aug 2026
Biome Australia capped FY26 with record $23.9 million sales and its flagship probiotic topping Australian pharmacy charts. The company signed an onshore manufacturing deal and expanded its proprietary probiotic clinical trial internationally.
Ada Torres
Ada Torres
29 July 2026
Biome Australia (ASX: BIO) edged close to breakeven in FY26, driven by $1.8 million in international sales across four markets and a 68% gross margin. The company is set to launch onshore manufacturing and a digital health platform to accelerate growth.
Ada Torres
Ada Torres
27 July 2026
Biome Australia has posted a 30% increase in FY26 sales revenue to $23.9 million, driven by strong domestic demand and strategic moves into onshore manufacturing and international markets.
Ada Torres
Ada Torres
1 July 2026
Biome Australia has inked a binding deal with Specialty Probiotics Australia to shift its Activated Probiotics manufacturing onshore, aiming to boost gross margins above 65% and streamline working capital within 18 months.
Ada Torres
Ada Torres
3 June 2026

Browse the archive

Full archive